Dear Editor,
To May 2022, the COVID-19 pandemic has claimed more than 6.28 million lives, with
more than 524 million confirmed cases worldwide. The recent emergence of highly transmissible
Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
triggered another major surge in both confirmed cases and deaths.
1
Ten COVID-19 vaccines have been approved by the World Health Organization (WHO) for
emergency use, including the two mRNA vaccines, BNT162b2 and mRNA-1273, and two Chinese
inactivated vaccines, CoronaVac and BBIBP-CorV. However, the rapid waning of vaccine-induced
virus-neutralizing antibody titers and the continuous emergence of variants of concern
(VOCs), including Alpha, Beta, Delta and Omicron, have created unprecedented challenges
in the eradication of COVID-19 pandemic.
2–4
Especially, the heavily mutated Omicron variant has been well characterized to escape
from most therapeutic monoclonal antibodies, as well as sera from convalescent patients
or fully vaccinated individuals.
5,6
Recent work indicated that neutralizing antibody against Omicron was absent or undetectable
in most Chinese populations who received two-dose inactivated vaccines,
7
while a booster dose with mRNA vaccine BNT162b2 showed significant superiority over
homologous booster in protection against Omicron.
7–9
However, the two commercial mRNA vaccines, encoding the full spike (S) protein of
SARS-CoV-2, are not available in mainland China. The “made-in-China” mRNA vaccine
candidate AWcorna (originally termed ARCoV), which encodes the receptor binding domain
(RBD) of SARS-CoV-2 S protein, is being tested in the final stage of multiple-center
phase III trials (https://clinicaltrials.gov/ct2/show/NCT04847102). It is of highly
priority and urgency to provide evidence to support a better boosting strategy in
mainland China for decision maker.
Herein, we reported the safety and immunogenicity of a third dose of heterologous
boosting with AWcorna in Chinese adults who have received two-dose inactivated vaccines.
The randomized clinical trial (ChiCTR2100053701) enrolled 300 adults (ages ≥ 18 years).
All eligible subjects received 2-dose priming vaccination with the inactivated vaccine,
CoronaVac or BBIBP-CorV. At about 6-month post-priming, all subjects were randomly
assigned to either the AWcorna (n = 200; heterologous) or CoronaVac (n = 100; homologous)
booster group (Supplementary information, Fig. S1a). In the AWcorna group, the median
age was 43.0 years (Interquartile rate, IQR: 36.5–49.0), and the CoronaVac group was
40.0 years (IQR: 34.0–48.5) (P = 0.5165) (Supplementary information, Table S1). There
were 116 (58%) and 55 (55%) male participants in the AWcorna and CoronaVac groups,
respectively (P = 0.6208). Meanwhile, no significant differences were observed in
the Body Mass Index (BMI), vital signs, and comorbid condition between the two groups
at the baseline (all P > 0.05). All subjects completed the enrollment vaccination
and three blood examinations consecutively at pre-booster or 0 days, 14 ± 2 days,
and 28 ± 2 days post-booster vaccination. Subsequently, the neutralization and IgG
antibody titers against wild-type (WT) SARS-CoV-2 and VOCs were assessed at pre-booster,
14- and 28-day post-booster by the standard cytopathic effect (CPE)-based assay and
ELISA, respectively (Supplementary information). The WHO standard IgG antibody (NIBSC
code 20/136) was used as a reference sample for all serological assays.
As expected, the live virus neutralization titers against WT SARS-CoV-2 were below
the detection limit before boosting in all participants from both groups (Fig. 1a).
Remarkably, AWcorna booster induced a 66.2-fold increase against WT SARS-CoV-2, and
the geometric mean titers (GMTs) reached 293.9 and 242.4 at 14 and 28 days post booster,
respectively (WHO Reference cut-off 1:139), while the GMTs in CoronaVac booster groups
was only 89.1 and 64.3, respectively (Fig. 1a; Supplementary information, Table S2).
Similarly, the neutralization antibody titers against the Delta variant also increased
significantly after the third dose booster either with AWcorna and CoronaVac, while
the GMTs in Awcorna groups were 5.1- and 6.5-fold higher than those in CoronaVac group
at 14 and 28 days post booster (Fig. 1b; Supplementary information, Table S2). In
addition, the increasing trends are similar in both 18–59 and ≥60 years old participants
(Supplementary information, Fig. S2a, b).
Fig. 1
Safety and immunogenicity of heterologous boosting with AWcorna in Chinese adults.
a Geometric mean titer (GMT) of neutralizing antibodies to live WT SARS-CoV-2. The
WHO reference serum (1000 IU/mL) was equivalent to a live viral neutralizing antibody
titer of 1:139 against WT. b GMT of neutralizing antibodies to the Delta variant.
The WHO reference was 1:213 against the Delta variant (the dash line in red). Eligible
participants primed with 2 doses of inactivated vaccine were randomly allocated to
AWcorna group (n = 200) and CoronaVac group (n = 100) to receive a booster dose. c
GMT of neutralizing antibodies to the Omicron variant was measured in the subgroup
(120 participants with the first 120 subject numbers, 80 from AWcorna and 40 from
CoronaVac group). Sera were measured 28 days after booster only, and thus no baseline
analysis was performed. d Seropositive rates (%) of neutralizing antibody to the Omicron
variant. e GMTs of anti-RBD IgG antibodies to WT SARS-CoV-2. The WHO reference (1000
binding antibody unit (BAU)/mL in serum) is equivalent to an RBD-specific IgG ELISA
antibody titer of 1:5490. The cutoff value for the response was 1:8 for live virus
neutralizing antibody and 1:10 for anti-RBD IgG. f The percentage of participants
with local adverse events (AEs). g The percentage of participants with systemic AEs.
These AEs were monitored in the 14-day window after the administration of the booster.
For a–c and e, GMT data are presented in box-and-whisker plots. The figures above
error bars indicate the percentage. P values were obtained from comparisons between
the two treatment groups using t-tests for log-transformed antibody or two-sided χ2
tests for categorical data (a–e).
Despite the neutralization antibody titers against the Omicron variant showed significant
reduction in comparison with those against WT in both groups, the GMTs against Omicron
maintained 28.1 at 28-day after AWcorna booster, while the GMT in the CoronaVac booster
group was only 6.4 (Fig. 1c; Supplementary information, Table S2). Most importantly,
83.75% of participants in the AWcorna booster group achieved the 1:8 threshold of
neutralization antibody titers against the Omicron compared to only 35% of participants
in the CoronaVac booster group (Fig. 1d; 95% Confidence Interval, CI: 30.82–63.84;
P < 0.0001). Moreover, the RBD-specific IgG antibodies titers also showed a sharp
increase in both booster groups, and the GMTs in AWcorna booster group were 6.8- and
7.1-fold higher than those in the CoronaVac booster group at both 14-day and 28-day
time points, respectively (all P < 0.0001) (Fig. 1e; Supplementary information, Table S3).
Taken together, these results demonstrate that heterologous boosting with AWcorna
induces higher neutralization and IgG antibodies against WT, Delta and Omicron variants
than homologous booster.
Additionally, we observed the safety profile of the booster dose of AWcorna. Solicited
local and systemic adverse events (AEs) were recorded within 30 min and in a window
of 0–14 days, and unsolicited AEs were documented within 0–28 days post-booster vaccination
(Supplementary information, Table S4). For both vaccines, pain at the injection site
is the most reported local AE (incidence rate, IR: 17% in AWcorna vs 2% in CoronaVac;
P < 0.0001), mostly at the Grade 1 level (Fig. 1f). Fever was the most common systemic
AE (IR: 33.5%), followed by headache (IR: 26.0%) and muscle aches (IR: 7.5%) in AWcorna
group (Fig. 1g). A total of 8 subjects reported grade 3 fever (IR: 4%) among the 200
participants in AWcorna group. For the CoronaVac group, headache represented the most
frequent systemic AE (IR: 7.0%), followed by fever (IR: 4.0%). No serious adverse
events (SAEs) were reported in both groups.
Collectively, our present study clearly demonstrated that a 3rd dose of heterologous
boosting with AWcorna was safe and protective against the circulating Delta and Omicron
variants. Compared with phase 1 trial, the total IRs of local and systemic AEs for
AWcorna booster showed significant improvement,
10
especially the IR of grade 3 fever that was reduced to 4% (Supplementary information,
Table S4), comparable to the other two approved mRNA vaccines.
11
The phase 1 trial of AWcorna only included 20 adults aged 18–59 (15 μg group), while
our present cohort enrolled 200 participants, including 10 subjects aged over 60.
The expansion of sample size and improvement in vaccine manufacturing technologies
contributed to the improved safety profile observed in our present study. The ongoing
international phase 3 trials with 28,000 participants will provide more about the
safety profile of AWcorna.
Previously, we have demonstrated that homologous boosting with AWcorna readily induced
high neutralization antibodies against WT and Omicron variant in mice.
12
and our present finding in human further supported heterologous booster with this
China-made mRNA vaccine AWcorna in Chinese populations. Many cities in China are under
the attack of Delta and Omicron variants, while few or no neuralization antibodies
against Omicron were detected in most Chinese populations.
7,13
A third dose booster has been recommended by the WHO and National Health Commission
of China. Of all COVID-19 vaccines generated from different technology platforms,
mRNA vaccine represent the most reasonable choice as either homologous or heterologous
booster. The neutralization titers against Delta and Omicron variants in AWcorna booster
group were 6.5-fold and 4.4-fold higher than those in CoronaVac booster group, respectively
(Fig. 1b, c), and the AWcorna booster induced the seroconversion of Omicron neutralization
in over 83% individuals (Fig. 1d). A third dose of S-targeting mRNA vaccine was evidenced
to increase the number of RBD-specific memory B cells with expanded potency and breadth,
thus contributing to the additional protection against VOCs including Omicron,
14,15
highlighting the rationale of RBD-targeting mRNA vaccine as a booster. Given that
Chinese population who have received three-dose inactivated vaccines is growing, additional
clinical trials are being conducted to assay the benefits of heterologous boosting
with AWcorna.
Finally, despite the vaccine effectiveness of AWcorna booster in preventing infection
by SARS-CoV-2 and other VOCs remains to be determined, the induction of potent neutralization
antibodies against WT and VOCs, as well as the affordable safety profile, support
the emergency use of AWcorna as heterologous booster in China. A more potent mRNA
vaccine and improved booster strategy should be warranted to meet the urgent and huge
need to stop the ongoing Omicron outbreaks in China and COVID-19 pandemic worldwide.
Supplementary information
Supplementary Information